ライフサイエンスコーパス: survival rate

1 No implants were lost (100% survival rate).

2 re and associated with a significantly lower survival rate.

3 Main outcome measurements were mean graft survival rate.

4 Na(+) and Cl(-), which directly affected the survival rate.

5 d bactericidal clearance and led to a better survival rate.

6 s clinical manifestations and an unfavorable survival rate.

7 el demonstrated a greater than 25% long-term survival rate.

8 e to drug resistance, contributing to a poor survival rate.

9 ditions during electroporation increased the survival rate.

10 orm of acute myeloid leukemia (AML) and poor survival rate.

11 ue to its poorest prognoses with a 7% 5-year survival rate.

12 al lung disease of unknown origin with a low survival rate.

13 chemoresistant recurrence and low five-year survival rate.

14 a poorer prognosis with significantly lower survival rates.

15 with high Rab7 expression display decreased survival rates.

16 effective therapies and face extremely poor survival rates.

17 se (pCR), disease-free survival, and overall survival rates.

18 urvival, and identify prognostic factors for survival rates.

19 e determined as prognostic factors affecting survival rates.

20 cinoma (HCC) has high relapse and low 5-year survival rates.

21 n aggressive form of lung cancer with dismal survival rates.

22 iff responses were associated with long-term survival rates.

23 educes PTB and dramatically improves newborn survival rates.

24 on displayed inferior overall and event-free survival rates.

25 increased incidence of bacteremia, and lower survival rates.

26 cell fractions, with significantly different survival rates.

27 ancer typically spreads rapidly and has poor survival rates.

28 he association between frailty and long-term survival rates.

29 fficacious than free antibiotics in terms of survival rates.

30 Kaplan-Meier curves were plotted to compare survival rates.

31 entify new, rapidly acting drugs to increase survival rates.

32 f breast cancer resulting in remarkably high survival rates.

33 nt, culture data, visual outcomes, and graft survival rates.

34 n was divided into three zones with relevant survival rates.

35 , lung and renal vascular leakage, and mouse survival rates.

36 nestlings, and assessed their body size and survival rates.

37 ection, which would greatly increase patient survival rates.

38 , has contributed to improvements in overall survival rates.

39 lung and kidney vascular leakage and reduced survival rates.

40 with faster metabolic rates to exhibit lower survival rates.

41 ants born extremely premature have increased survival rates(1,2).

42 LAPC was 20.1 months and the overall 5-year survival rate 12.5%.

43 an [SD] age, 65.8 [17.2] years; 62% men), ED survival rate (23%) and survival-to-discharge rate (16%)

44 versus 85%, P<0.001), and had overall worse survival rates (3% versus 13%; P=0.007) compared with IH

45 year (46% versus 91%, P = 0.003), and 5-year survival rates (39% versus 90%, P = 0.002) were observed

46 004), 2-year (46% vs 91%,p=0.003) and 5-year survival rates (39% vs 90%,p=0.002) were observed in the

47 uction in tumor size (~47%) and an increased survival rate (~43%) without any demonstrable toxicity t

48 nificance, overall, 5-year and 10-year graft survival rates (57.1%, 94.7% and 53.8%, respectively) in

49 significance, overall, 5- and 10-year graft survival rates (57.1%, 94.7%, and 53.8%, respectively) i

50 ction as the transgenic mice showed a higher survival rate (79.17% VS.

51 ctive 5-year event-free survival and overall survival rates (95% CI) were 77.0% (64.8% to 85.5%) and

52 gbirds, we compared nesting and postfledging survival rates across 18 species from eight studies in t

53 The overall survival rate after extracorporeal cardiopulmonary resus

54 The overall survival rate after HSCT (median follow-up, 20 months) w

55 The 1, 3, and 5 year unadjusted survival rates after LT were 72%, 63% and 60%, respectiv

56 This study compares graft and patient survival rates after transplantation of livers donated a

57 The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36

58 Its impact on the survival rate among out-of-hospital cardiac arrest patie

59 CMS4), which is characterized by the poorest survival rate among the four CMSs.

60 r patients with high-risk neuroblastoma, but survival rate among these patients remains low.

61 The 1-year survival rate among these patients was 38%.

62 cohort experienced significantly lower graft survival rates among AA than white recipients (kidney 5

63 We compared 10-week survival rates among those with and without CMV viremia.

64 recipient mice showed more than 80% 6-month survival rate and comparable body weight to control mice

65 RvD1 therapy increased the survival rate and controlled parasite replication in mic

66 he use of different equations for the vector survival rate and host-to-vector transmission rates resu

67 ferences between grafts and their control in survival rate and locus specific DNA alteration.

68 time of diagnosis, it has a very low 5-year survival rate and may become the second leading cause of

69 completely eliminated habitat differences in survival rate and nestling body size suggest that urban

70 Administration of a C5-blocking mAb improved survival rate and offered functional and histopathologic

71 T3 caused the highest reduction in survival rate and trunk diameter, followed by T4 and T2,

72 eatly reduced the significant differences in survival rates and body sizes between urban and forest b

73 We used Kaplan-Meier analysis to estimate survival rates and Cox regression to estimate the risk o

74 more, the clear connection between increased survival rates and immune receptor-IDH1 mutant complemen

75 longed mechanical ventilation experience low survival rates and incur high healthcare costs.

76 l dispersal, and its growth is determined by survival rates and productivity.

77 her estimated the effect of PFAS on apparent survival rates and re-sighting probabilities using a 10-

78 er discordances yield insights into variable survival rates and timing of arrival of enslaved people

79 3/2004, and H7N9 A/Anhui/1/2013 by improving survival rates and weight loss.

80 dications for grafting, complications, graft survival rate, and causes of graft failure were analyzed

81 tal predictor of beneficial outcomes, higher survival rate, and decreased hospitalization duration.

82 ), delayed graft function, patient and graft survival rates, and renal function.

83 ed for at least 5 years, 10-year conditional survival rates are high.

84 Graft survival rate at 1, 5, 10, 15, 20 and 30 years was 83.6%

85 Progression-free survival rate at 36 months after R-CHOP in the MHG group

86 The survival rate at 60 minutes was 90% in trigeminal nerve

87 irculation rate was 3675 of 8754 (41.9%) and survival rate at hospital discharge was 788 of 8754 (9%)

88 The survival rate at the implant level was 90% in the test g

89 Tooth survival rate at the latest follow-up for those with an

90 The overall corneal graft survival rates at 1, 5, 10, 15, and 20 years were 91%, 6

91 Overall survival rates at 12 weeks were 50% in the single-fracti

92 Estimated on-device survival rates at 2 years were 72%, 71%, and 55% in the

93 Kidney allograft survival rates at 3, 5, 7, and 10 years after diagnosis

94 e bounds: high, intermediate, and low 1-year survival rates at respectively [Formula: see text] ([For

95 e effects of trigeminal nerve stimulation on survival rate, autonomic nervous system activity, hemody

96 s no significant difference in diabetes-free survival rates between untreated and PEG/RBV-treated per

97 Oral cavity cancer has a low 5-y survival rate, but outcomes improve when the disease is

98 tromal cells did not alter clinical score or survival rate, but reduced levels of systemic interleuki

99 malignant paediatric brain tumour, has a 70% survival rate, but standard treatments often lead to dev

100 bacterial infections is crucial to improving survival rates by enabling treatment with appropriate an

101 prevented ischemic brain injury and improved survival rates by restoring S-nitrosylated protein level

102 and control broods had similar body size and survival rates; (c) urban supplemented nestlings had lar

103 ated liver disease and post-LT, with post-LT survival rates comparable to other indications.

104 TO patients had a higher 3-year survival rate compared to non-TO patients (75% vs 55%, l

105 o 15% absolute higher functionally favorable survival rate compared with more conservative approaches

106 esistant S. aureus challenge showed a higher survival rate compared with untreated controls (60% for

107 ble lesions was associated with twice-higher survival rate compared with untreated unstable lesions (

108 ients had a trend for higher recurrence-free survival rates compared to HBV and HCV-HCC cases.

109 s had longer overall but not recurrence-free survival rates compared to patients with viral-associate

110 nhanced autophagy and improved intracellular survival rates compared to those of wild-type bacteria i

111 s, decitabine treatment resulted in superior survival rates compared with cytarabine.

112 easible and effective, resulting in improved survival rates compared with historical controls.

113 e shown that obese, diabetic mice have lower survival rates compared with nondiabetic mice.

114 well as longer progression-free and overall survival rates, compared to targeting of fewer somatic a

115 DAA-treated persons had longer diabetes-free survival rates, compared to untreated and PEG/RBV-treate

116 rts, but it has not been shown whether avian survival rates covary with latitude worldwide.

117 Cell survival rate (CSR) is a very important parameter in bio

118 Survival rates decrease significantly when localized pro

119 vely eradicate E. coli while not harming the survival rate, development, and biological functions of

120 experienced extraordinary advancements with survival rates doubling for many disorders.

121 he age of 50 years, and has favorable 5-year survival rates due to early cancer detection and availab

122 of NSCLC would likely increase response and survival rates due to timely intervention.

123 similar post-transplant recipient and graft survival rates exceeding 85% and comparable to the bench

124 Overall, the 1-year survival rate following liver transplantation is lower t

125 The 5-year survival rate for all eyes was 75% with 95% confidence i

126 The 5-year overall survival rate for all patients was 87%.

127 The 5-y survival rate for HNSCC remains at ~50%, and improving t

128 sure (IOP) level and secondary measures were survival rate for IOP control, glaucoma medication use,

129 The survival rate for patients with ovarian cancer has chang

130 The survival rate for PK was 94.4%, 80.4%, and 72.0% at 1, 5

131 However, the progression-free survival rate for the CRPC patients on antiandrogen ther

132 Notably, the survival rate for the high expression levels of Lrp5, CS

133 kitt (LMB) chemotherapy regimen has improved survival rates for children with mature B-cell non-Hodgk

134 Survival rates for nontrauma surgical emergencies were i

135 r estimated abandonment-sensitive event-free survival rates for patients undergoing upfront and delay

136 Although survival rates for patients without organ dysfunction is

137 ack of standard therapies and poorer overall survival rates for patients.

138 The 5-year event-free survival and overall survival rates for the 598 patients were 88.2% (95% CI,

139 Survival rates for those infected with resistant isolate

140 cRNA-seq profiles are highly correlated with survival rate from The Cancer Genome Atlas (TCGA).

141 io, 0.72 [CI, 0.55-0.96], P=0.025) and lower survival rates (global P value 0.029; >75% Hispanic: odd

142 A broad range of survival rates have been described for adenocarcinoma of

143 aggressive cancer phenotype, with low 5-year survival rates, high 3-year recurrence rates, and increa

144 ce (PVR) before LT was associated with worse survival rate (HR 1.91, 95% CI 1.07-3.74, p=0.04).

145 VU0155069 strongly enhances survival rate in cecal ligation and puncture (CLP)-induc

146 in controls; p < 0.001) yielded the same ICU survival rate in the two groups (n = 34, 77% vs n = 29,

147 While the presence of frailty reduced the survival rate in women, no effect was observed in men.

148 rexpression correlated with disease-specific survival rates in breast cancer.

149 emporal changes in the use of treatments and survival rates in dialysis patients with an AMI.

150 A7A) confers significantly decreased patient survival rates in ER(+) breast cancer.

151 nalysis revealed that 5- and 10-year patient survival rates in group 1 (92.5% and 70.4%) were signifi

152 Improved survival rates in HICs have been achieved through multid

153 cute graft pyelonephritis, patient and graft survival rates in LUTM at 10 years were similar to other

154 of intraperitoneal OVASC-1 tumor burden and survival rates in mice shows that the administration of

155 The 5-y survival rates in nonmalignant SBS-IF patients who initi

156 research funding may contribute to stagnant survival rates in pancreatic ductal adenocarcinoma (PDAC

157 igh expression of NEK2 was predictive of low survival rates in patients who had residual disease foll

158 air temperatures have been shown to improve survival rates in several other Arctic and northern terr

159 the efficacy of hemodialysis, as well as the survival rate, in CKD patients.

160 The 30-day survival rates increased from 31.3% (control group) to 3

161 3D-ECM exhibited greater attachment, higher survival rate, increased insulin content, and enhanced g

162 utant variants of R273 in p53 have different survival rates, indicating that the DNA-contact inhibiti

163 ve treatment for advanced KS; therefore, the survival rate is low.

164 ients being in an advanced stage wherein the survival rate is very low.

165 ort to reduce toxicity while preserving high survival rates is an appropriate therapeutic objective c

166 ained challenging to treat in children, with survival rates lagging well behind those observed at ini

167 hth-most common cancer worldwide, with a 5-y survival rate <50%.

168 rtality rate of 33 to 46% and the low 5-year survival rate (<45%).

169 Outcomes included 24-hour survival rates, mean arterial pressure, lactate, hemoglo

170 ic improvement in the 5-year cancer-specific survival rate of 0.17% (95% confidence interval, 0.06-0.

171 ity and mortality remain high, with a 5-year survival rate of 25% after hospitalization for HFrEF.

172 hs (95% CI 16.6-28.1), with a 3-year overall survival rate of 36.5% (28.4-44.6).

173 el, demonstrating an 8-year landmark overall survival rate of 37%.

174 interval [CI], 2.2-5.4 years) with a 5-year survival rate of 58.7%.

175 ent failed in 37 eyes (23.7%), with a 5-year survival rate of 68.0% and an estimated time to 75% surv

176 improved long-term outcome, with an overall survival rate of 71% (95% CI, 62 to 79) at 5 years.

177 iest human malignancies, has a dismal 5-year survival rate of 9%.

178 erall survival rate of 95% and an event-free survival rate of 92%), and encouraging outcomes after al

179 h a previous apical surgery had a cumulative survival rate of 92%.

180 tion (HSCT) in children (offering an overall survival rate of 95% and an event-free survival rate of

181 ncer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is

182 ian SECA trial demonstrated a 5-year overall survival rate of approximately 60%, notwithstanding earl

183 ll adhesions, negatively correlated with the survival rate of colon cancer patients and that depletio

184 The five-year survival rate of epithelial ovarian cancer (EOC) is appr

185 Cell encapsulation may enhance the survival rate of grafted cells, but the therapeutic effe

186 odification (IP) being performed or not, the survival rate of implants treated for peri-implantitis w

187 rain exposure and significantly improved the survival rate of mice with neuronal-specific ablation of

188 owth in vivo, and subsequently increased the survival rate of mice.

189 n cases of early diagnosis results in a 5-yr survival rate of nearly 60%, the prognosis for patients

190 mortality in women, with an expected 5-year survival rate of only 47%.

191 ic ductal adenocarcinoma (PDAC) has a 5-year survival rate of only 8% and is estimated to be the seco

192 Five-year survival rate of OvCa ranges from 30-92%, depending on t

193 , 0.5-10 years), the 6-year progression-free survival rate of patients who underwent cRT or NFT was,

194 one of the deadliest cancers, and the 5-year survival rate of patients with metastasis is extremely l

195 ck of curative treatment modalities, the 5-y survival rate of PDAC patients is one of the lowest of a

196 The survival rate of rats in the no-anticoagulation group, r

197 Median ex vivo ring-stage survival rate of these isolates was very high (12.2%; 95

198 irradiation and in correlation with the low survival rate of UV-treated VdCmr1 mutants.

199 n and moderate loss of horizontal cells, the survival rate of various cell types is very high.

200 Despite a five-year survival rate of ~70%, nearly all patients incur adverse

201 nificantly different (P < 0.001) with 5-year survival rates of 100%, 69% with 95% CI, 16 to 93, and 4

202 disease-specific, relapse-free, and overall survival rates of 100%, 98%, and 99%, respectively.

203 ecurrence had 1-, and 2-year post-recurrence survival rates of 20 and 6% compared with 45 and 22% for

204 that were associated with 5-yr disease-free survival rates of 27.8% and 0.2%, respectively (P < 0.00

205 d on extracorporeal membrane oxygenation had survival rates of 70%.

206 ioblastoma (GBM) has one of the worst 5-year survival rates of all cancers.

207 /CD19(+)-depleted grafts produced comparable survival rates of around 80%, although with a high rate

208 under hypoxic conditions, thereby increasing survival rates of arrested progeny during hypoxia.

209 chanisms of the widespread decline in marine survival rates of Atlantic salmon (Salmo salar) over the

210 The success and survival rates of goniotomy, trabeculotomy+/-trabeculect

211 l oceans is a crucial factor influencing the survival rates of higher trophic levels, food web struct

212 cation and release in IECs and increased the survival rates of infected animals.

213 there were no significant differences in the survival rates of infected ILC-deficient mice and wild-t

214 or radiation therapies, with 5-year relative survival rates of just 19%.

215 the bone having poor prognosis and long-term survival rates of less than 30% in patients with metasta

216 recurrent or metastatic disease have 5-year survival rates of less than 30%.

217 ly rare and lethal form of the disease shows survival rates of less than a year.

218 JNK1/2 activities positively correlates with survival rates of lung, cervical and head and neck squam

219 Average survival rates of mechanically-sorted larvae were over 9

220 The incidence and patient survival rates of melanoma have increased over the last

221 we compared the overall and recurrence-free survival rates of NAFLD HCC cases to patients with HBV a

222 estations, management and in-ICU and 6-month survival rates of patients with those most severe thyroi

223 aim of the present article was to determine survival rates of root resection procedure and reasons f

224 The 5- and 10-year survival rates of the treated teeth were 85.0% and 72.7%

225 The 5- and 10-year survival rates of the treated teeth were 86.5% and 74.3%

226 nsistently disappointing with 5-year overall survival rates of ~10%.

227 urrence of arterial complications and a high survival rate, on which the overall medical care seems t

228 e goal of this study was to assess trends in survival rates over time in cancer patients admitted to

229 impact on the outcomes of patients with AML, survival rates remain low due to a high incidence of rel

230 However, overall survival rates remain unacceptably poor, with only 65% o

231 lesions at diagnosis is poor, and their 5-yr survival rate remains below 30%.

232 e ability of ERalpha antagonists to increase survival rates, resistance to these therapies is an all-

233 egeneration by increasing NSCs proliferation/survival rates, restoring a nearly original DG mass, pro

234 ure estimated here, non-zero germination and survival rates resulted in high establishment probabilit

235 A hospital's risk-standardized survival rate (RSSR) for in-hospital cardiac arrest has

236 The 5-year postinduction DFS and overall survival rates (+/- SE) of children randomly assigned to

237 h MAGL-specific inhibitor, JZL184, increased survival rate significantly in the mouse xenograft model

238 R-T to PR-T after 1 month had a higher graft survival rate than patients receiving IR-T at last follo

239 achieved better overall and progression-free survival rates than sorafenib in unresectable HCC.

240 7 expression and having significantly poorer survival rates than the other classes.

241 ol broods had smaller body size and nestling survival rates than those in forest control broods; (b)

242 plemented nestlings had larger body size and survival rates than those in urban control broods; and c

243 ents with group 4 disease had more favorable survival rates than those with group 3 medulloblastoma.

244 , the post-transplant outcomes are good with survival rates that are significantly higher when compar

245 We compared metabolic rates and annual survival rates that we measured across 46 species, and f

246 Chemotherapy has improved survival rates to approximately 70%; however, children a

247 ant recipients experience comparable patient survival rates to first and second transplants, regardle

248 f a high mutation rate, resulting in similar survival rates to low mutation BCs.

249 upplemented broods had similar body size and survival rates to nestlings in forest control broods.

250 ients with nonshockable rhythm (change in ED survival rate trend, 1.3% [95% CI, 0.89%-1.74%]; P<0.001

251 ber of barren siliques and a higher seedling survival rate under heat.

252 Survival rates vary dramatically among species and predi

253 Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR (P<0

254 n follow-up of 26 months, the 2-year overall survival rate was 74% (95% confidence interval, 62-81).

255 The overall survival rate was 87%.

256 The survival rate was 96.1%, and the success rate was 83.7%

257 The 5-year survival rate was between 50 and 87%.

258 Halyomorpha halys adult survival rate was higher when their nutrient index (EXA

259 on-intensive care unit patients, a 19% lower survival rate was observed in voriconazole-resistant cas

260 Three-year cumulative graft survival rate was significantly (P < .001) lower for eye

261 Five-year patient and graft survival rates were 100% and 95%, respectively.

262 Twenty-four-hour survival rates were 100%, 16.7%, and 0% in the PEG-20k,

263 P = .005), and 3- and 5-year recurrence-free survival rates were 20.40% and 17.05% versus 5.87% and 3

264 The progression-free survival rates were 21% (95% confidence interval [CI], 1

265 , 95% CI 0.58-0.82); 8-year landmark overall survival rates were 37% (95% CI 31-42) in the pertuzumab

266 The overall survival rates were 37% (95% CI, 33 to 42) at 4 years an

267 mated 6-, 12-, and 18-month progression-free survival rates were 51.3% (90% CI, 38.2% to 64.5%), 46.2

268 Two-year PFS and overall survival rates were 52% (95% CI, 32.4% to 71.6%) and 92%

269 espectively (HR, 0.62; P = .03); and overall survival rates were 62% and 56%, respectively (HR, 0.84;

270 The 2-year progression-free survival rates were 63% (95% CI, 49% to 81%) and 87% (95

271 The overall Kaplan-Meier graft survival rates were 64.7% in the postoperative average f

272 Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respect

273 survival, relapse-free survival, and overall survival rates were 67.7% (95% CI, 55.9% to 79.4%), 72.9

274 Five-year survival rates were 72% (95% CI, 67-76) with incomplete

275 In the uDCD group, 1-, 3-, and 5-year graft survival rates were 73.3%, 65.1%, and 63.6%, respectivel

276 The 1-, 2-, and 3-year overall survival rates were 76%, 62%, and 54%, and 71%, 56%, and

277 The 30-day, 1-year, and 3-year actuarial survival rates were 77%, 53%, and 43%, respectively.

278 Overall 30-day, 1-year, and 5-year survival rates were 81.2%, 45.3%, and 11.5%, respectivel

279 Survival rates were 83.5% (95% CI, 81.4%-85.5%) and 18.6

280 The 5-year event-free and overall survival rates were 83.7% +/- 1.1% and 89.5% +/- 0.9%, r

281 tively, and the 6-month and 12-month overall survival rates were 84.9% and 64.3% respectively.

282 [HR], 0.80; P = .03); breast cancer-specific survival rates were 88% and 82%, respectively (HR, 0.62;

283 The estimated 5-year event-free and overall survival rates were 92.0% +/- 3.9% and 96.0% +/- 2.8%, r

284 ressed; respective 24-month progression-free survival rates were 95.8% and 89.8%.

285 Survival rates were analyzed using Kaplan-Meier estimate

286 Five-year relative survival rates were estimated by race and ethnicity, his

287 Temporal trends in survival rates were examined using proportional-hazards

288 Godwit survival rates were high throughout the annual cycle, bu

289 Survival rates were improved for all 10 types of general

290 X release, tumour growth inhibition and mice survival rates were influenced by the physicochemical pr

291 Overall and graft survival rates were not statistically different accordin

292 treated with the addition of ATG, and graft survival rates were significantly better with grade II r

293 The overall survival rates were significantly higher in the NAFLD-HC

294 and patient (96.7% vs 95.4%, P = .70) 1-year survival rates were similar.

295 Five-year transplant-free survival rates were unfavorable for cluster 1 (47.6%; 95

296 ute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regime

297 ls at RT also showed a trend towards greater survival-rates when cultured (74.3 +/- 2.9% and 67.7 +/-

298 in the United States and demonstrates a 38% survival rate, which is comparable to other reports in t

299 inoculated with S. Typhimurium led to a 50% survival rate, while 100% of infected mice in the no-DMG

300 nt disease response types affecting epidemic survival rates, with important implications for understa